Cost-Effectiveness of Vaccination of Older Adults with an MF59<sup>®</sup>-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden

Cost-Effectiveness of Vaccination of Older Adults with an MF59<sup>®</sup>-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden

Individuals aged 65 years and above are at increased risk of complications and death from influenza compared with any other age group. Enhanced vaccines, as the MF59<sup>®</sup>-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose quadrivalent influenza vaccine (HD-QIV), pr...

Full description

Bibliographic Details
Main Authors: Jorge Jacob, Tor Biering-Sørensen, Lars Holger Ehlers, Christina H. Edwards, Kristin Greve-Isdahl Mohn, Anna Nilsson, Jonas Hjelmgren, Wenkang Ma, Yuvraj Sharma, Emanuele Ciglia, Joaquin Mould-Quevedo
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Vaccines
Subjects:
cost-effectiveness
seasonal influenza
adjuvanted influenza vaccine
Nordic countries
Online Access:https://www.mdpi.com/2076-393X/11/4/753

Internet

https://www.mdpi.com/2076-393X/11/4/753

Similar Items